Drug Type Live biotherapeutic products |
Synonyms Nonpathogenic yeast, S. boulardii CNCM I-745 |
Target- |
Mechanism Bacteria replacements, Microbiome modulators |
Therapeutic Areas- |
Active Indication- |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseEarly Phase 1 |
First Approval Date- |
Regulation- |
Start Date18 Jan 2024 |
Sponsor / Collaborator- |
Start Date11 Sep 2023 |
Sponsor / Collaborator |
Start Date20 Jan 2023 |
Sponsor / Collaborator |
Study | Phase | Population | Analyzed Enrollment | Group | Results | Evaluation | Publication Date |
---|
Phase 4 | 317 | vuahpilhqs(ofgvxppuoh) = ktdgufqmvz lixlqaxvsv (ykpnikwuaf, 56.5 - 72.8) | Positive | 09 Sep 2022 | |||
(4-strain mixture of Bacillus clausii (O/C, SIN, N/R, T)) | vuahpilhqs(ofgvxppuoh) = wturmylswq lixlqaxvsv (ykpnikwuaf, 69.9 - 86.1) |